Fibromyalgia

Condition: Fibromyalgia  |  Category: Inflammation and Immune Health  |  Reviewed by: Brian Lamkin, DO

What Is Fibromyalgia?

Fibromyalgia is a chronic pain condition defined by widespread musculoskeletal pain lasting longer than three months, accompanied by fatigue, cognitive dysfunction (commonly called "fibro fog"), and non-restorative sleep. It affects approximately 2 to 4 percent of the population, with a significant female predominance. The underlying mechanism is central sensitization: the spinal cord and brain amplify pain signals, producing a state in which normal stimuli are perceived as painful (allodynia) and mildly painful stimuli produce disproportionate pain (hyperalgesia).

This is not a psychological condition. Functional MRI studies demonstrate measurable differences in pain processing regions of the brain in fibromyalgia patients. Elevated levels of substance P in cerebrospinal fluid, reduced descending inhibitory pain modulation, and glial cell activation in the dorsal horn of the spinal cord have all been documented. The question is not whether fibromyalgia is real but rather what is driving the central nervous system into this amplified state. That question is where functional medicine provides the most significant clinical value.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Conventional rheumatology diagnoses fibromyalgia by symptom criteria and manages it with medications that modulate pain perception. Functional medicine asks what is driving the central sensitization and treats those upstream mechanisms.

Neuroinflammation and Glial Cell Activation

Microglia and astrocytes in the spinal cord and brain produce pro-inflammatory cytokines that sensitize pain-processing neurons, lowering the threshold at which signals are perceived as painful. This neuroinflammatory state is maintained by systemic inflammation from gut dysbiosis, chronic infection, environmental toxin exposure, and metabolic dysfunction. Elevated hs-CRP in fibromyalgia patients correlates with symptom severity and is an independent predictor of treatment response to anti-inflammatory intervention.

HPA Axis Dysregulation

Fibromyalgia patients consistently demonstrate flat cortisol diurnal patterns with blunted morning cortisol response and reduced cortisol reactivity to stress. Cortisol is a primary endogenous anti-inflammatory and pain-modulating hormone. When the HPA axis produces inadequate cortisol at the times it is most needed, both inflammatory signaling and pain perception increase. DHEA-S depletion frequently accompanies the cortisol dysfunction, removing the neurosteroid counterbalance that supports mood and pain modulation.

Sleep Architecture Disruption

Alpha-wave intrusion into stage 3 and stage 4 deep sleep is one of the most consistently documented findings in fibromyalgia research. Deep sleep is when growth hormone secretion peaks, tissue repair occurs, and descending pain inhibition is restored. When deep sleep is disrupted, these restorative processes fail, producing the non-restorative sleep and morning stiffness that are hallmarks of the condition. Addressing sleep architecture is one of the highest-leverage interventions available.

Thyroid Dysfunction and Gut Dysbiosis

Subclinical hypothyroidism is significantly more prevalent in fibromyalgia patients than in age-matched controls. Low free T3 impairs pain modulation pathways and reduces the metabolic rate of tissue repair. Gut dysbiosis produces systemic inflammation through lipopolysaccharide translocation, impairs tryptophan metabolism (reducing serotonin availability for pain modulation), and disrupts the gut-brain axis signaling that influences central pain processing.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

Fibromyalgia evaluation requires markers that identify the upstream drivers of central sensitization, not just confirmation that the pain is present.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient told fibromyalgia is "just a label": A 45-year-old woman with 7 years of widespread pain, fatigue, and cognitive dysfunction. Told by multiple providers that fibromyalgia is a diagnosis given when nothing else is found. hs-CRP 3.8, cortisol flat throughout the day, DHEA-S depleted, vitamin D 18 ng/mL, free T3 in the lower quartile. Five identifiable, measurable, treatable drivers that no one had ever tested for.
• The patient on pregabalin with progressive weight gain and brain fog: Pregabalin reduced pain by approximately 20 percent but produced 15 pounds of weight gain, worsening brain fog, and peripheral edema. The medication side effects were compounding the metabolic and cognitive burden of the condition. Transitioning to low-dose naltrexone (for glial cell modulation) plus targeted anti-inflammatory and HPA axis support produced superior pain reduction without the side effects.
• Fibromyalgia that began after a viral illness: Widespread pain, fatigue, and cognitive dysfunction developing 4 to 6 weeks after a confirmed viral infection. Post-infectious neuroinflammation and HPA axis disruption as the triggering mechanism. Anti-inflammatory intervention, immune modulation, and HPA restoration produced significant improvement over 3 to 4 months.
• The patient with concurrent IBS: Fibromyalgia with chronic bloating, alternating bowel habits, and food reactivity. Comprehensive stool analysis revealed significant dysbiosis with reduced butyrate-producing species. Gut restoration reduced both GI symptoms and pain severity concurrently, confirming the gut-brain axis as a primary driver of her central sensitization.

Treatment and Optimization Strategy

Multi-Driver Intervention

Fibromyalgia treatment at The Lamkin Clinic targets the specific combination of upstream drivers identified through comprehensive testing. The goal is to reduce central sensitization by resolving the mechanisms that produce it.

What Most Doctors Miss

• No biological evaluation is performed: standard fibromyalgia diagnosis involves symptom criteria and exclusion of other conditions. The upstream drivers (inflammation, cortisol, thyroid, vitamin D, gut) are never measured because the diagnostic framework does not require it.
• Central sensitization is treated as the endpoint: medications modulate pain perception at the central level but do not address what is producing and maintaining the sensitized state. The neuroinflammation, HPA dysfunction, and sleep disruption that drive sensitization continue unchecked.
• Small fiber neuropathy is not screened for: up to 50 percent of fibromyalgia patients may have concurrent small fiber neuropathy producing peripheral pain generation. Skin punch biopsy can confirm this, and it changes the treatment approach.
• The gut-brain axis is not assessed: gut dysbiosis is an independent driver of both systemic inflammation and central pain processing disruption, yet GI function and microbiome status are not evaluated in standard fibromyalgia care.

When to Seek Medical Care

If you experience widespread pain lasting longer than three months accompanied by fatigue, cognitive difficulty, non-restorative sleep, or sensitivity to stimuli, a comprehensive evaluation for fibromyalgia and its upstream drivers is warranted. This is especially important if conventional medications have produced inadequate results, or if your pain began after a viral illness, traumatic event, or period of sustained stress.

At The Lamkin Clinic, fibromyalgia evaluation includes hs-CRP, cortisol pattern assessment, full thyroid panel, vitamin D, DHEA-S, vitamin B12, fasting insulin, and gut health markers, reviewed together as an integrated profile of central sensitization drivers.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Fibromyalgia

At The Lamkin Clinic, fibromyalgia evaluation begins with comprehensive biological testing: hs-CRP, cortisol pattern, full thyroid panel, vitamin D, DHEA-S, metabolic markers, and gut health assessment. We identify the specific drivers of central sensitization in each patient and build a multi-driver intervention protocol targeting those mechanisms directly. Low-dose naltrexone, anti-inflammatory support, HPA axis restoration, sleep optimization, and thyroid and gut treatment are implemented based on the individual lab profile.

Related Conditions

Related Symptoms